ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipe

ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance

Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipeline Re-commercialization Efforts

Targets sNDA Filing for Cortrophin Gel by Q1 2020

Records Initial Royalties on Commercial Sales of Yescarta

BAUDETTE, Minn., Aug. 7, 2018 /PRNewswire/ --

For the second quarter 2018:

Net revenues of $47.3 million, an increase of 6% as compared to the same period in 2017

GAAP net income of $2.8 million and diluted GAAP earnings per share of $0.23

Adjusted non-GAAP EBITDA of $19.0 million

Adjusted non-GAAP diluted earnings per share of $1.13

ANI Pharmaceuticals, Inc. ( ANI ) (NASDAQ: ANIP) today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. The Company will host its earnings conference call this morning, August 7, 2018, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875. The conference ID is 9878939.

Arthur S. Przybyl, President and CEO, stated,

In the second quarter of 2018 ANI continued to successfully execute on its strategy to grow the brand and generic business platforms and to advance our key pipeline assets. In addition, today, we announced that we acquired WellSpring, a contract development and manufacturing business located near Toronto, Canada in order to expand our third business platform, contract manufacturing, and to increase our capacity to re-commercialize our pipeline of acquired ANDAs that require a tech transfer.

During the second quarter we acquired a basket of 23 generic products from IDT and we acquired a portfolio of six generic products, a license, supply, and distribution agreement for a seventh generic product, and related equipment from the Impax/Amneal business

combination. We believe these acquisitions provide compelling short and long-term opportunities for continued revenue and EBITDA growth for ANI. These opportunities are discussed in further detail below.

In June we launched Cholestyramine, our tenth product launch from our pipeline of acquired ANDAs, and our fourth generic product launch in the second quarter, after successfully completing a manufacturing site transfer to our Baudette facilities. We also entered into an agreement with ClarusOne, a large buying consortium, that we believe will provide us with an opportunity to increase our generic product revenues.

In July we launched our internally-developed morphine sulfate oral solution product, as well as two of the branded products we acquired in December 2017, Arimidex and Casodex, and we expect to launch the two Atacand branded products in the ANI label in October of

2018. Finally, we have advanced our Cortrophin product, and have announced a target FDA supplemental NDA filing date, which is discussed in further detail below.

ANI Updates Guidance for the Full Year 2018

ANI's estimates are based upon actual results for the six months ending June 30, 2018 and projected results for the remaining six months of the year. ANI's full year 2018 guidance reflects management's current assumptions regarding customer relationships, product pricing, prescription trends, competition, inventory levels, cost of sales, operating costs, timing of research and development spend, taxes, and the anticipated timing of future product launches, integration and contribution of recent acquisitions and other key events. For the twelve months ending December 31, 2018, ANI is providing guidance on net revenue, adjusted non-GAAP EBITDA and

adjusted non-GAAP diluted earnings per share.

The following table summarizes 2018 guidance:

($ in millions except EPS figures)

Generic Pharmaceutical

Second Quarter Revenue Results and Update

Revenues from sales of generic pharmaceuticals decreased 4%, to $30.2 million from $31.5 million in the prior period, primarily due to volume decreases for Fenofibrate and sales decreases for Propranolol ER driven by price, tempered by the impact of a full quarter of sales of Diphenoxylate Hydrochloride and Atropine Sulfate and the second quarter 2018 launch of Ezetimibe-Simvastatin. So far in 2018, ANI has launched five generic products: Morphine Sulfate Oral Solution, Cholestyramine for Oral Suspension, Ezetimibe-Simvastatin, Desipramine, and Felbamate, increasing its generic commercialized product portfolio to a total of 29 products. In June, ANI entered into an Agreement with ClarusOne, one of the three largest buying consortia, that will allow ANI to compete for additional generic business. Finally, we are

excited to announce that we have been granted priority review status for an ANDA filing submitted through one of our development partners. The assigned GDUFA date for this product is in April 2019.

Key Generic Pipeline Products

Branded Pharmaceutical Products

Second Quarter Revenue Results and Update

Revenues from sales of branded pharmaceuticals decreased 10%, to $10.5 million from $11.7 million in the prior period, primarily due to lower revenue from Inderal LA due to decreased unit sales, partially offset by increased sales of Inderal XL and InnoPran XL. In July, ANI launched two branded products, Arimidex and Casodex, in the ANI label,

increasing the number of branded products sold under the ANI's label to nine. ANI expects to launch two additional branded products in the ANI label, Atacand and Atacand HCT in October 2018.

Key Brand Pipeline Products

Vancocin Oral Solution Update

ANI is currently advancing a commercialization effort for Vancocin oral solution. Following completion of ongoing formulation and manufacturing optimization, ANI intends to file a prior approval supplement ( PAS ) in September 2018. This product will be manufactured at ANI's site in Baudette, Minnesota and will compete in a market that currently exceeds $450 million annually.

Cortrophin Gel Re-commercialization Update

In the second quarter of 2018, ANI continued to advance the manufacture of Corticotropin active pharmaceutical ingredient ( API ), completing the manufacture of four successful pilot-scale API batches and initiating the manufacture of commercial scale batches of Corticotropin API. ANI is on track to initiate API process validation and registration batch manufacturing in the first quarter of 2019.

ANI continued to manufacture Cortrophin Gel drug product, which has been placed on stability. The work has been valuable in identifying critical process parameters and manufacturing and quality attributes of the drug product. ANI intends to initiate commercial scale drug product manufacturing activities this year.

Following ANI's request for a Type C meeting with the FDA in the fourth quarter

of 2017, the FDA granted the meeting and provided an initial response in March 2018. Further oral and written communications with the FDA occurred in the second quarter of 2018. Based on these communications, the FDA's expectations for our supplemental NDA filing have been further defined and incorporated into ANI's regulatory plan. The FDA feedback has not fundamentally changed ANI's regulatory strategy and has not altered the timeline for the project. As a result, ANI expects to file a supplemental NDA by the first quarter of 2020.

For further details, please see ANI's Cortrophin Gel Re-commercialization Milestone Update in Table 5.

Contract Manufacturing

Second Quarter Revenue Results and Update

Contract manufacturing revenue increased by 10% to $1.7 million from $1.5 million in the prior year period, primarily as a

result of the timing and volume of customer orders.

WellSpring Acquisition

Today, ANI acquired WellSpring Pharma Services Inc., a contract development and manufacturing organization ( CDMO ), located near Toronto in Oakville, Canada. With an employee base of about 100, WellSpring is a well-established CDMO with capabilities in solid oral, semi-solids and liquids that operates out of a 100,000 square foot site that ANI acquired as part of the transaction. WellSpring has a diverse customer base, focused on both brand and generic drug products. The company currently manufactures 17 commercial products for 11 different customers and is assisting customers on 13 additional products that are in development or awaiting FDA approval. The site manufactures drug product for both the U.S. and Canadian prescription drug markets and has substantial capacity.

anticipates substantial synergy in the WellSpring acquisition. Through this acquisition ANI intends to not only broaden its existing CMO platform but also to utilize the acquired facility and capabilities to expand and accelerate the re-commercialization effort associated with ANI's pipeline of acquired ANDAs that require a tech transfer. WellSpring currently generates $15 to $20 million dollars in annual revenues and ANI expects the acquisition will be accretive to Adjusted EBITDA beginning in 2019.

We are excited to welcome the WellSpring customers and the WellSpring employees to ANI.

Royalty and Other Income

Second Quarter Revenue Result and Update

Royalty and other income increased to $4.9 million from $0.1 million, primarily due to the royalties received on sales of Atacand , Atacand HCT , Arimidex , and

Casodex . These product royalties will decrease as a direct result of ANI transferring these products into the ANI label branded product. In addition, ANI recognized royalties related to Yescarta , which is discussed in further detail below.

Key Royalty Product: Yescarta

ANI is entitled to a percentage of global Yescarta net sales as well as a portion of certain product milestones, such as the recent positive opinion issued by the European Medicines Agency ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ). These revenue streams originate from assets acquired in the BioSante transaction and subsequent licensing arrangements between ANI and various parties including Kite Pharma, Inc. ANI recognized $0.9 million of royalties related to the product in Q2 2018.

Second Quarter Results

For the three months ended June 30, 2018, ANI reported net revenues of $47.3 million, an increase of 6% from $44.8 million in the prior year period, due to the following factors:

Revenues from sales of generic pharmaceuticals decreased 4%, to $30.2 million from $31.5 million in the prior period, primarily due to volume decreases for Fenofibrate and sales decreases for Propranolol ER driven by price, tempered by the impact of a full quarter of sales of Diphenoxylate Hydrochloride and Atropine Sulfate, as well as the second quarter 2018 launch of Ezetimibe-Simvastatin.

Revenues from sales of branded pharmaceuticals decreased 10%, to $10.5 million from $11.7 million in the prior period, primarily due to lower revenue from Inderal LA due to decreased unit sales, partially offset by increased sales of Inderal XL and InnoPran XL, both of which were acquired in the first quarter of 2017, and which were re-launched under our label in the first quarter of 2018.

Contract manufacturing revenue increased by 10% to $1.7 million from $1.5 million in the prior year period, primarily as a result of the timing and volume of customer orders.

Royalty and other income increased to $4.9 million from $0.1 million, primarily due to the royalties received on sales of Atacand , Atacand HCT , Arimidex , and Casodex , as well as royalties from Yescarta sales and milestones.

Operating expenses increased to $40.0 million for the three months ended June 30, 2018, from $37.8 million in the prior year period. The increase was primarily due to a $3.0 million increase in research and development as compared with the prior period, as a result of $1.3 million of in-process research and development, which was recognized as research and development expense in relation to the asset acquisition from Impax/Amneal, as well as the timing of work on development projects, primarily the Cortrophin gel re-commercialization project and work on the ANDAs purchased in 2014 and 2015. In addition,

selling, general, and administrative expense increased by $2.6 million due to increased personnel and related costs and depreciation and amortization increased by $1.2 million due primarily to the amortization of the product rights for Atacand , Atacand HCT , Arimidex , and Casodex , which were acquired in December 2017. These increases were partially offset by the $4.5 million decrease in cost of sales, due to decreased sales of products subject to profit-sharing arrangements.

Cost of sales as a percentage of net revenues decreased to 35% during the three months ended June 30, 2018, from 40% during same period in 2017, excluding the $3.2 million of net inventory step-up costs related to sales of Inderal XL, InnoPran XL , and Inderal LA in the second quarter of 2017. The decrease was primarily due to increased royalty income, change in product

mix toward higher-margin brand products, and lower sales of products subject to profit-sharing arrangements.

Net income was $2.8 million for the three months ended June 30, 2018, as compared to net income of $2.7 million in the prior year period. The effective tax rate for the three months ended June 30, 2018 was 21%.

Diluted earnings per share for the three months ended June 30, 2018 was $0.23, based on 11,789 thousand diluted shares outstanding, as compared to diluted earnings per share of $0.23 in the prior year period. Adjusted non-GAAP diluted earnings per share was $1.13, as compared to adjusted non-GAAP diluted earnings per share of $0.98 in the prior year period. For a reconciliation of adjusted non-GAAP diluted earnings per share to the most directly comparable GAAP financial measure, please see Table 4.

Results for Six Months Ended June 30,

For the six months ended June 30, 2018, ANI reported net revenues of $93.8 million, an increase of 15% from $81.4 million in the prior year period, due to the following factors:

Revenues from sales of generic pharmaceuticals decreased 8%, to $53.4 million from $58.1 million in the prior period, primarily due to volume decreases for Fenofibrate and sales decreases for Propranolol ER driven by price, tempered by the impact of the second quarter 2017 launch of Diphenoxylate Hydrochloride and Atropine Sulfate and the second quarter 2018 launch of Ezetimibe-Simvastatin.

Revenues from sales of branded pharmaceuticals increased 38%, to $27.1 million from $19.7 million in the prior period, primarily due to sales of Inderal XL and InnoPran XL, both of which were acquired in the first quarter of 2017, and which were re-launched under our label in the first quarter of 2018.

Contract manufacturing revenue decreased by 21% to $2.6 million from $3.3 million in the prior year period, primarily as a result of the timing and volume of customer orders.

Royalty and other income increased to $10.6 million from $0.3 million, primarily due to the royalties received on sales of Atacand , Atacand HCT , Arimidex , and Casodex , as well as royalties from Yescarta sales and milestones.

Operating expenses increased to $80.0 million for the six months ended June 30, 2018, from $69.8 million in the prior year period. The increase was primarily due to a $4.2 million increase in selling, general, and administrative as compared with the prior period, as a result of increases in personnel and related costs. Research and development expense increased by $3.5 million as compared with the prior period, primarily as a result of $1.3 million of in-process research and development, which was recognized as research and development expense in relation to the asset acquisition from Impax/Amneal, as well as

the timing of work on development projects, primarily the Cortrophin gel re-commercialization project and work on the ANDAs purchased in 2014 and 2015. In addition, depreciation and amortization increased by $2.7 million due to the amortization of the product rights for Atacand , Atacand HCT , Arimidex , and Casodex , which were acquired in December 2017.

Excluding the $5.6 million of net inventory step-up related to the sales and write off Inderal XL and InnoPran XL in the six months ended June 30, 2018 and $4.7 million of net inventory step-up costs related to sales of Inderal XL, InnoPran XL , and Inderal LA in the six months ended June 30, 2017, cost of sales as a percentage of net revenues decreased to 34% during the six months ended June 30, 2018, from 41% during same period in 2017, primarily as a change in product mix

towards higher-margin brand products and lower sales of products subject to profit-sharing arrangements.

Net income was $5.0 million for the six months ended June 30, 2018, as compared to net income of $3.8 million in the prior year period. The effective tax rate for the six months ended June 30, 2018 was 21%.

Diluted earnings per share for the six months ended June 30, 2018 was $0.42, based on 11,748 thousand diluted shares outstanding, as compared to diluted earnings per share of $0.33 in the prior year period. Adjusted non-GAAP diluted earnings per share was $2.45, as compared to adjusted non-GAAP diluted earnings per share of $1.72 in the prior year period. For a reconciliation of adjusted non-GAAP diluted earnings per share to the most directly comparable GAAP financial measure, please see Table 4.

Selected Balance Sheet Data

ANI generated $31.5 million of positive cash flows from operations in the six months ended June 30, 2018. In December 2017, ANI entered into a credit agreement with Citizens Bank, N.A. that included a $75 million term loan and a $50 million line of credit. The $75 million term loan was used to pay down ANI's former $25.0 million line of credit and to purchase from AstraZeneca AB and AstraZeneca UK Limited the right, title, and interest in the NDAs and the U.S. rights to market Atacand , Atacand HCT , Arimidex , and Casodex , for $46.5 million in cash. The $50 million line of credit currently remains undrawn. In April 2018, ANI purchased from IDT Australia, Limited the ANDAs for 23 previously-marketed generic drug products and API for four of

the acquired products for $2.7 million in cash and a single-digit royalty on net profits from sales of one of the products. In May 2018, ANI purchased from Impax/Amneal the approved ANDAs for three previously-commercialized generic drug products, the approved ANDAs for two generic drug products that have not yet been commercialized, the development package for one generic drug product, a license, supply, and distribution agreement for a generic drug product with an ANDA that is pending approval, and certain manufacturing equipment required to manufacture one of the products, for $2.3 million in cash.

ANI Product Development Pipeline

ANI's pipeline consists of 75 products, addressing a total annual market size of $4.5 billion, based on data from IQVIA. Of these 75 products, 70 were acquired and of these acquired products, ANI expects that 55 can be commercialized

based on either CBE-30s or prior approval supplements filed with the FDA.

Non-GAAP Financial Measures

The Company's fiscal 2018 guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP diluted earnings per share is not reconciled to the most comparable GAAP measure. This is due to the inherent difficulty of forecasting the timing or amount of items that would be included in a reconciliation to the most directly comparable forward-looking GAAP financial measures. Because a reconciliation is not available without unreasonable effort, it is not included in this release.

Adjusted non-GAAP EBITDA

ANI's management considers adjusted non-GAAP EBITDA to be an important financial indicator of ANI's operating performance, providing investors and analysts with a useful measure of operating results unaffected by non-cash stock-based

compensation and differences in capital structures, tax structures, capital investment cycles, ages of related assets, and compensation structures among otherwise comparable companies. Management uses adjusted non-GAAP EBITDA when analyzing Company performance.

Adjusted non-GAAP EBITDA is defined as net income/(loss), excluding tax expense, interest expense, depreciation, amortization, the excess of fair value over cost of acquired inventory, stock-based compensation expense, expense from acquired in-process research and development, transaction expenses, and other income / expense. Adjusted non-GAAP EBITDA should be considered in addition to, but not in lieu of, net income or loss reported under GAAP. A reconciliation of adjusted non-GAAP EBITDA to the most directly comparable GAAP financial measure is provided in Table 3.